Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1Advanced Malignant Solid Tumors 1

Interventions

Cyclophosphamide 209fludarabine phosphate 184Azacitidine 159fludarabine 142Busulfan 138Tacrolimus 119Mycophenolic Acid 111Cytarabine 110Whole-Body Irradiation 106Peripheral Blood Stem Cell Transplantation 98Antilymphocyte Serum 97Melphalan 90Filgrastim 87Cyclosporine 83Decitabine 82Methotrexate 79venetoclax 63Granulocyte Colony-Stimulating Factor 56Radiotherapy 49Stem Cell Transplantation 48Thiotepa 47Cord Blood Stem Cell Transplantation 42Clofarabine 42thymoglobulin 41Specimen Handling 35Etoposide 35Methylprednisolone 34Sirolimus 33Injections 27Biopsy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myelodysplastic Syndromes × TAK-243 × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡